Market Research Logo

Global Cephalosporin Drugs Market 2015-2019

About cephalosporins

Cephalosporins are bactericidal antibiotics and act by inhibiting cell wall synthesis. They inhibit a wide variety of gram-positive and gram-negative bacteria. They are considered broad-spectrum antibiotics with similar activities to those of ampicillin. They are sometimes grouped into generations by their antimicrobial properties. Cephalosporin drugs can be grouped into five classes or generations. The gram-negative antimicrobial property significantly increases with each newer generation of cephalosporin.

Technavio's analysts forecast the global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019.

Covered in this report

In this report, Technavio covers the present scenario and growth prospects of the global cephalosporin drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria.

Technavio's report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA
Key vendors
  • Allergan
  • Astellas
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sandoz
  • Teva Pharmaceuticals
Other prominent vendors
  • Abbott
  • Aspen Pharmacare
  • AstraZeneca
  • Aurobindo Pharma
  • Basilea Pharmaceuticals
  • Baxter
  • Biocon
  • Corden Pharma
  • Cornerstone Therapeutics
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Flynn Pharma
  • Hospira
  • Incepta Pharmaceuticals
  • Johnson & Johnson
  • Kyorin Pharmaceutical
  • Lupin Pharmaceuticals
  • Orchid Pharma
  • Par Pharmaceutical
  • Pernix Therapeutics
  • Sanofi
  • Shionogi
  • Sun Pharmaceutical
  • Takeda Pharma
  • Theravance Biopharma
  • Wockhardt
Market driver
  • Special regulatory designation for pipeline molecules
  • For a full, detailed list, view our report
Market challenge
  • Development of drug resistance
  • For a full, detailed list, view our report
Market trend
  • Use of combination therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Cephalosporin Drugs Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Cephalosporin Drugs Market: Allergan, Astellas, Bristol-Myers Squibb, GSK, Merck, Pfizer, Sandoz and Teva

Other Prominent Vendors in the market are: Abbott, Aspen Pharmacare, AstraZeneca, Aurobindo Pharma, Basilea Pharmaceuticals, Baxter, Biocon, Corden Pharma, Eli Lilly, F. Hoffmann-La Roche, Flynn Pharma, Hospira, Incepta Pharmaceuticals, Johnson & Johnson, Kyorin Pharmaceutical, Lupin Pharmaceuticals, Orchid Pharma, Par Pharmaceutical, Pernix Therapeutics, Sanofi, Shionogi, Sun Pharmaceutical, Takeda Pharma, Theravance Biopharma, and Wockhardt.

Commenting on the report, an analyst from Technavio’s team said: “The increased approvals and use of combination drugs is an emerging trend in the global cephalosporin drugs market. Combination therapies are found to show better efficacy than monotherapies. Also, the use of monotherapies leads to easy development of resistance. This can be avoided by the judicious use of combination drugs.”

According to the report, the increased awareness of diseases and their treatment options helps detect and treat infections during their early stages. The European Antibiotic Awareness Day is celebrated on November 18 every year to raise awareness about antibiotic resistance and promote the judicious use of antibiotics. Such programs about the disease and treatment options increase the treatment-seeking population, driving the growth of the market.

Further, the report states that most drugs in the cephalosporin market are generics, resulting in decreased revenue for the products. Some drugs that have expired and have a generic form as of today include cefuroxime axetil, ceftazidime, and cefprozil.

Companies Mentioned

Allergan, Astellas, Bristol-Myers Squibb, GSK, Merck, Pfizer, Sandoz, Teva, Abbott, Aspen Pharmacare, AstraZeneca, Aurobindo Pharma, Basilea Pharmaceuticals, Baxter, Biocon, Corden Pharma, Eli Lilly, F. Hoffmann-La Roche, Flynn Pharma, Hospira, Incepta Pharmaceuticals, Johnson & Johnson, Kyorin Pharmaceutical, Lupin Pharmaceuticals, Orchid Pharma, Par Pharmaceutical, Pernix Therapeutics, Sanofi, Shionogi, Sun Pharmaceutical, Takeda Pharma, Theravance Biopharma, Wockhardt.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Cephalosporin overview
    • Introduction
      • Table Evolution of cephalosporin drugs
    • Precursors of cephalosporins
      • Table Overview of the activity of different generations of cephalosporin drugs
    • Mechanism of action
    • General principles for use of antibiotics
      • Table General principles involved in use of antibiotics
    • Clinical uses
    • Epidemiology
      • Table Estimated number of cases for nosocomial infections in the US 2011
      • Table Number of cases of E.coli in the UK 2012-2014
  • Overview on the consumption of antibiotics
    • Latin America
    • Europe
    • APAC
  • Legislation relating to antibiotic use in the US
    • Table Legislation relating to the use of antibiotics in the US
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global cephalosporin drugs market 2014-2019 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by generation of cephalosporin
    • Table Global cephalosporin drugs market segment by generation
    • First-generation cephalosporins
    • Second-generation cephalosporins
    • Third-generation cephalosporins
    • Fourth-generation cephalosporins
    • Fifth-generation cephalosporins
      • Table Overview of activity of different generations of cephalosporins
      • Table Evolution of different generations of cephalosporin drugs
  • Market segmentation by route of administration
    • Table Global cephalosporin drugs market segment by route of administration
    • Injection
    • Oral
      • Table Different generations of cephalosporin drugs by route of administration
  • Geographical segmentation
    • Segmentation of global cephalosporin drugs market by geography
      • Table Global cephalosporin drugs market segment by geography 2014
      • Table Global cephalosporin drugs market revenue by geography 2014-2019 ($ millions)
    • Cephalosporin drugs market in Americas
      • Table Cephalosporin drugs market in Americas 2014-2019 ($ millions)
      • Table Percentage share of cephalosporin market in Americas
      • Table Percentage share of market by generation of cephalosporin in the US based on revenue 2014
    • Cephalosporin drugs market in EMEA
      • Table Cephalosporin drugs market in EMEA 2014-2019 ($ millions)
      • Table Percentage share of cephalosporin drugs market in EMEA
      • Table Percentage share of market by generation of cephalosporin in EU based on revenue 2014
    • Cephalosporin drugs market in APAC
      • Table Cephalosporin drugs market in APAC 2014-2019 ($ millions)
  • Market drivers
    • Special regulatory designation for pipeline molecules
    • Rise in prevalence of infectious diseases
    • Increase in awareness
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Development of drug resistance
      • Table Cephalosporin resistant strains according to the period of development of resistance
    • High generic penetration
    • Weak pipeline
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Use of combination therapies
    • Increase in M&A
    • Increasing irrational use of cephalosporins
  • Vendor landscape
    • Competitive scenario
    • Market share analysis 2014
      • Table Allergan: YoY growth and revenue generated from net product sales of anti-infective drugs 2011-2013 ($ millions)
      • Table Allergan: Key takeaways
      • Table Astellas: Key takeaways
      • Table Bristol-Myers Squibb: Key takeaways
      • Table GSK: Key takeaways
      • Table Merck: Key takeaways
      • Table Pfizer: Key takeaways
      • Table Sandoz: Key takeaways
      • Table Teva Pharmaceuticals: Key takeaways
    • Other prominent vendors
  • Key vendor analysis
    • Allergan
      • Table Allergan: Business segmentation by product revenue 2014
      • Table Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Allergan: Geographical segmentation by revenue 2014
    • Astellas
      • Table Astellas: Product segmentation by revenue 2015
      • Table Astellas: Product segmentation by revenue 2014 and 2015 ($ billions)
      • Table Astellas: Geographical segmentation by revenue 2015
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb: Segmentation by revenue 2014
      • Table Bristol-Myers Squibb: Segmentation by revenue 2013 and 2014 ($ billions)
      • Table Bristol-Myers Squibb: Geographical segmentation by revenue 2014
    • GSK
      • Table GSK: Business segmentation by revenue 2014
      • Table GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table GSK: Geographical segmentation by revenue 2014
    • Merck
      • Table Merck: Business segmentation by revenue 2014
      • Table Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Merck: Geographical segmentation by revenue 2014
    • Pfizer
      • Table Pfizer: Business segmentation by revenue 2014
      • Table Pfizer business segmentation by revenue 2013 and 2014 ($ billions)
      • Table Pfizer: Geographical segmentation by revenue 2014
    • Sandoz
      • Table Sandoz: Business segmentation by revenue 2014
    • Teva Pharmaceuticals
      • Table Teva Pharmaceuticals: Business segmentation by revenue 2014
      • Table Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014
      • Table Teva Pharmaceuticals: Geographical segmentation by revenue 2014
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report